The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL

Lisa M. Butler, Vasilios Liapis, Stelios Bouralexis, Katie Welldon, Shelley Hay, Le M. Thai, Agatha Labrinidis, Wayne D. Tilley, David M. Findlay, Andreas Evdokiou

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

While the apoptosis-inducing ligand Apo2L/TRAIL is a promising new agent for the treatment of cancer, the sensitivity of cancer cells for induction of apoptosis by Apo2L/TRAIL varies considerably. Identification of agents that can be used in combination with Apo2L/TRAIL to enhance apoptosis in breast cancer cells would increase the potential utility of this agent as a breast cancer therapeutic. Here, we show that the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), can sensitize Apo2L/TRAIL-resistant breast cancer cells to Apo2L/TRAIL-induced apoptosis. Importantly, neither Apo2L/TRAIL alone, nor in combination with SAHA, affected the viability of normal human cells in culture. Apo2L/TRAIL-resistant MDA-MB-231 breast cancer cells, generated by long-term culture in the continuous presence of Apo2L/TRAIL, were resensitized to Apo2L/TRAIL-induced apoptosis by SAHA. The sensitization of these cells by SAHA was accompanied by activation of caspase 8, caspase 9 and caspase 3 and was concomitant with Bid and PARP cleavage. The expression of the proapoptotic protein, Bax, increased significantly with SAHA treatment and high levels of Bax were maintained in the combined treatment with Apo2L/TRAIL. Treatment with SAHA increased cell surface expression of DR5 but not DR4. Interestingly, SAHA treatment also resulted in a significant increase in cell surface expression of DcR1. Taken together, our findings indicate that the use of these 2 agents in combination may be effective for the treatment of breast cancer.

LanguageEnglish
Pages944-954
Number of pages11
JournalInternational Journal of Cancer
Volume119
Issue number4
DOIs
Publication statusPublished - 15 Aug 2006

Keywords

  • Apo2L
  • Apo2L/TRAIL
  • Apoptosis
  • Breast cancer
  • Histone deacetylase inhibitors
  • SAHA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Butler, Lisa M. ; Liapis, Vasilios ; Bouralexis, Stelios ; Welldon, Katie ; Hay, Shelley ; Thai, Le M. ; Labrinidis, Agatha ; Tilley, Wayne D. ; Findlay, David M. ; Evdokiou, Andreas. / The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. In: International Journal of Cancer. 2006 ; Vol. 119, No. 4. pp. 944-954.
@article{ed30e878072d46c1adca2d8c9a72a82d,
title = "The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL",
abstract = "While the apoptosis-inducing ligand Apo2L/TRAIL is a promising new agent for the treatment of cancer, the sensitivity of cancer cells for induction of apoptosis by Apo2L/TRAIL varies considerably. Identification of agents that can be used in combination with Apo2L/TRAIL to enhance apoptosis in breast cancer cells would increase the potential utility of this agent as a breast cancer therapeutic. Here, we show that the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), can sensitize Apo2L/TRAIL-resistant breast cancer cells to Apo2L/TRAIL-induced apoptosis. Importantly, neither Apo2L/TRAIL alone, nor in combination with SAHA, affected the viability of normal human cells in culture. Apo2L/TRAIL-resistant MDA-MB-231 breast cancer cells, generated by long-term culture in the continuous presence of Apo2L/TRAIL, were resensitized to Apo2L/TRAIL-induced apoptosis by SAHA. The sensitization of these cells by SAHA was accompanied by activation of caspase 8, caspase 9 and caspase 3 and was concomitant with Bid and PARP cleavage. The expression of the proapoptotic protein, Bax, increased significantly with SAHA treatment and high levels of Bax were maintained in the combined treatment with Apo2L/TRAIL. Treatment with SAHA increased cell surface expression of DR5 but not DR4. Interestingly, SAHA treatment also resulted in a significant increase in cell surface expression of DcR1. Taken together, our findings indicate that the use of these 2 agents in combination may be effective for the treatment of breast cancer.",
keywords = "Apo2L, Apo2L/TRAIL, Apoptosis, Breast cancer, Histone deacetylase inhibitors, SAHA",
author = "Butler, {Lisa M.} and Vasilios Liapis and Stelios Bouralexis and Katie Welldon and Shelley Hay and Thai, {Le M.} and Agatha Labrinidis and Tilley, {Wayne D.} and Findlay, {David M.} and Andreas Evdokiou",
year = "2006",
month = "8",
day = "15",
doi = "10.1002/ijc.21939",
language = "English",
volume = "119",
pages = "944--954",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

Butler, LM, Liapis, V, Bouralexis, S, Welldon, K, Hay, S, Thai, LM, Labrinidis, A, Tilley, WD, Findlay, DM & Evdokiou, A 2006, 'The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL', International Journal of Cancer, vol. 119, no. 4, pp. 944-954. https://doi.org/10.1002/ijc.21939

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. / Butler, Lisa M.; Liapis, Vasilios; Bouralexis, Stelios; Welldon, Katie; Hay, Shelley; Thai, Le M.; Labrinidis, Agatha; Tilley, Wayne D.; Findlay, David M.; Evdokiou, Andreas.

In: International Journal of Cancer, Vol. 119, No. 4, 15.08.2006, p. 944-954.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL

AU - Butler, Lisa M.

AU - Liapis, Vasilios

AU - Bouralexis, Stelios

AU - Welldon, Katie

AU - Hay, Shelley

AU - Thai, Le M.

AU - Labrinidis, Agatha

AU - Tilley, Wayne D.

AU - Findlay, David M.

AU - Evdokiou, Andreas

PY - 2006/8/15

Y1 - 2006/8/15

N2 - While the apoptosis-inducing ligand Apo2L/TRAIL is a promising new agent for the treatment of cancer, the sensitivity of cancer cells for induction of apoptosis by Apo2L/TRAIL varies considerably. Identification of agents that can be used in combination with Apo2L/TRAIL to enhance apoptosis in breast cancer cells would increase the potential utility of this agent as a breast cancer therapeutic. Here, we show that the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), can sensitize Apo2L/TRAIL-resistant breast cancer cells to Apo2L/TRAIL-induced apoptosis. Importantly, neither Apo2L/TRAIL alone, nor in combination with SAHA, affected the viability of normal human cells in culture. Apo2L/TRAIL-resistant MDA-MB-231 breast cancer cells, generated by long-term culture in the continuous presence of Apo2L/TRAIL, were resensitized to Apo2L/TRAIL-induced apoptosis by SAHA. The sensitization of these cells by SAHA was accompanied by activation of caspase 8, caspase 9 and caspase 3 and was concomitant with Bid and PARP cleavage. The expression of the proapoptotic protein, Bax, increased significantly with SAHA treatment and high levels of Bax were maintained in the combined treatment with Apo2L/TRAIL. Treatment with SAHA increased cell surface expression of DR5 but not DR4. Interestingly, SAHA treatment also resulted in a significant increase in cell surface expression of DcR1. Taken together, our findings indicate that the use of these 2 agents in combination may be effective for the treatment of breast cancer.

AB - While the apoptosis-inducing ligand Apo2L/TRAIL is a promising new agent for the treatment of cancer, the sensitivity of cancer cells for induction of apoptosis by Apo2L/TRAIL varies considerably. Identification of agents that can be used in combination with Apo2L/TRAIL to enhance apoptosis in breast cancer cells would increase the potential utility of this agent as a breast cancer therapeutic. Here, we show that the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), can sensitize Apo2L/TRAIL-resistant breast cancer cells to Apo2L/TRAIL-induced apoptosis. Importantly, neither Apo2L/TRAIL alone, nor in combination with SAHA, affected the viability of normal human cells in culture. Apo2L/TRAIL-resistant MDA-MB-231 breast cancer cells, generated by long-term culture in the continuous presence of Apo2L/TRAIL, were resensitized to Apo2L/TRAIL-induced apoptosis by SAHA. The sensitization of these cells by SAHA was accompanied by activation of caspase 8, caspase 9 and caspase 3 and was concomitant with Bid and PARP cleavage. The expression of the proapoptotic protein, Bax, increased significantly with SAHA treatment and high levels of Bax were maintained in the combined treatment with Apo2L/TRAIL. Treatment with SAHA increased cell surface expression of DR5 but not DR4. Interestingly, SAHA treatment also resulted in a significant increase in cell surface expression of DcR1. Taken together, our findings indicate that the use of these 2 agents in combination may be effective for the treatment of breast cancer.

KW - Apo2L

KW - Apo2L/TRAIL

KW - Apoptosis

KW - Breast cancer

KW - Histone deacetylase inhibitors

KW - SAHA

UR - http://www.scopus.com/inward/record.url?scp=33745895281&partnerID=8YFLogxK

U2 - 10.1002/ijc.21939

DO - 10.1002/ijc.21939

M3 - Article

VL - 119

SP - 944

EP - 954

JO - International Journal of Cancer

T2 - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -